Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10303954 | Psychiatry Research | 2012 | 6 Pages |
Abstract
Sexual dysfunction is a major side effect of selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs). We conducted a genome-wide association study to identify the genetic factors contributing to the risk of SSRI/SNRI-induced sexual dysfunction by testing 186 320 single nucleotide polymorphism (SNP) markers in a cohort of 201 Japanese major depression patients including 36 with sexual dysfunction induced by SSRI (paroxetine or fluvoxamine) or SNRI (milnacipran). The Cochran-Armitage trend test showed that 11 SNPs, tightly clustered in a distinct region on chromosome 14q21.3, were associated with SSRI/SNRI-induced sexual dysfunction at a genome-wide significance level after false discovery rate (FDR) correction, and the strongest SNP association was with rs1160351 (P = 3.04 Ã 10â 7, risk ratio = 2.92, 95% confidence interval (CI) = 1.79-4.76). These SNPs mapped to the intronic region of the MDGA2 gene. A Manhattan plot showed that the strong association peak remained in MDGA2 after adjustment for sex and age in a multivariable logistic regression analysis although P values increased slightly and became non-significant. Replication studies with larger sample sizes are required to validate this exploratory study, but our findings may provide insights into the genetic basis of sexual dysfunction induced by SSRI/SNRI.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Kouichi Kurose, Kazuyuki Hiratsuka, Kazuya Ishiwata, Jun Nishikawa, Shinpei Nonen, Junichi Azuma, Masaki Kato, Masataka Wakeno, Gaku Okugawa, Toshihiko Kinoshita, Toru Kurosawa, Ryuichi Hasegawa, Yoshiro Saito,